Alessandra Ricco

Bari, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications

Prophylaxis and management of thromboembolism in pnh patients: an italian survey.

Prophylaxis and management of thromboembolism in pnh patients: an italian survey.

Journal: Annals of hematology
Published: February 03, 2026

One Grammar, Many Labels: Revisiting the Continuum of Myeloid Neoplasms.

One Grammar, Many Labels: Revisiting the Continuum of Myeloid Neoplasms.

Journal: Hematological oncology
Published: January 29, 2026

Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy.

Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy.

Journal: Therapeutic advances in hematology
Published: December 24, 2025

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Journal: Hematological oncology
Published: November 13, 2025

Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study.

Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study.

Journal: European journal of haematology
Published: July 14, 2025

Real-world evidence of pegcetacoplan in patients with paroxysmal nocturnal haemoglobinuria: A nationwide Italian study.

Real-world evidence of pegcetacoplan in patients with paroxysmal nocturnal haemoglobinuria: A nationwide Italian study.

Journal: British journal of haematology
Published: November 16, 2024

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

Journal: Cancer
Published: October 24, 2024

IRF4 dysregulation in chronic myelomonocytic leukemia: another brick in the wall of myelodysplastic/myeloproliferative neoplasms.

IRF4 dysregulation in chronic myelomonocytic leukemia: another brick in the wall of myelodysplastic/myeloproliferative neoplasms.

Journal: Annals of hematology
Published: June 28, 2024

Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.

Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.

Journal: American journal of hematology
Published: April 11, 2024

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Journal: NEJM evidence
Published: February 06, 2024

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Journal: Annals of hematology
Published: November 13, 2023

A Long-Term Follow-Up Study in Immune-Mediated Thrombotic Thrombocytopenic Purpura: What Are the Outcomes?

A Long-Term Follow-Up Study in Immune-Mediated Thrombotic Thrombocytopenic Purpura: What Are the Outcomes?

Journal: Journal of clinical medicine
Published: September 25, 2023
Showing 1-12 of 49

Last Updated: 09/26/2026